Geron Corporation, a commercial-stage biotech company, is advancing growth through the commercialization of its first-in-class telomerase inhibitor, RYTELO (imetelstat), approved for lower-risk myelodysplastic syndromes (MDS). The company launched RYTELO in the U.S. in mid-2024 and secured European Commission approval in early 2025, with plans to extend market access internationally. Alongside commercialization efforts, Geron progresses its phase 3 IMpactMF trial in relapsed/refractory myelofibrosis (MF), with interim overall survival data expected in late 2026. Despite promising clinical data and strong intellectual property protections, Geron reported significant net losses and negative operating cash flows as of fiscal 2025 but maintains ample liquidity to support ongoing development and commercialization initiatives.